Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | TTK | P33981 | 4/20 | 0.58 |
| ▸ | BRD4 | O60885 | 5/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.58 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.53 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203886 | 0.95 | PLK1 (0.74) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203986 | 0.94 | PLK1 (0.71) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203461 | 0.94 | PLK1 (0.71) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203349 | 0.92 | PLK1 (0.69) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1204132 | 0.92 | PLK1 (0.68) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1202863 | 0.89 | PLK1 (0.67) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203822 | 0.89 | PLK1 (0.79) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL2396096 | 0.89 | PLK1 (0.79) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203641 | 0.88 | PLK1 (0.67) | PLK1RAD52TTKBRD4BRDT | |
| SCHEMBL1203548 | 0.87 | PLK1 (0.77) | PLK1RAD52TTKBRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2234809-B1 | EXTERIOR WINDOW FILM | CPFILMS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9303132-B2 | Exterior window film | CPFILMS INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| CN-101918215-B | outer window film | CPFILMS INC. (US) | 2015-09-23 | — | — | CN | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110027553-A1 | Exterior Window Film | CPFILMS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2234809-A2 | EXTERIOR WINDOW FILM | CPFilms Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090181242-A1 | Exterior window film | ENNISS JAMES P | 2009-07-16 | — | — | US | disclosed |
| WO-2009087575-A2 | EXTERIOR WINDOW FILM | CPFILMS INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | PLK1 355/4885RAD52 2823/4885TTK 153/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PLK1 23/4885RAD52 1278/4885TTK 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.